Next-generation anti-CD20 mAbs in clinical development
| Antibody . | Type . | Format . | Properties (compared with rituximab) . | Sponsor . | Stage of development . |
|---|---|---|---|---|---|
| Ofatumumab86-92 | I | Fully human IgG1 | Increased CDC | Genmab AC | FDA approved for refractory CLL phase 3 trials in NHL and autoimmune diseases |
| Ocrelizumab (PRO70769)93,94 | I | Humanized IgG1 (2H7) | Increased binding to FcγRIIIa and decreased CDC | Genentech/Roche/Biogen | Phase 3 trials in NHL and autoimmune diseases |
| Veltuzumab95-97 | I | Humanized IgG1 | Slower off-rate | Immunomedics | Phase 1/2 in NHL and ITP (including subcutaneous delivery) |
| AME-133V98 | I | Humanized IgG1 with modified Fc | Increased binding to CD20 and FcγRIIIa and increased ADCC | Applied Molecular Evolution/Eli Lilly | Phase 1/2 in NHL |
| PRO13192199 | I | Humanized IgG1 (ocrelizumab) with modified Fc | Increased FcγRIIIa binding and ADCC | Genentech | Phase 1/2 in NHL and CLL |
| GA101100-108 | II | Humanized IgG1 with afucosylated Fc | Enhanced FcγRIIIa binding, ADCC, and direct PCD | Glycart/Roche | Phase 2 in NHL and CLL phase 3 in CLL |
| Antibody . | Type . | Format . | Properties (compared with rituximab) . | Sponsor . | Stage of development . |
|---|---|---|---|---|---|
| Ofatumumab86-92 | I | Fully human IgG1 | Increased CDC | Genmab AC | FDA approved for refractory CLL phase 3 trials in NHL and autoimmune diseases |
| Ocrelizumab (PRO70769)93,94 | I | Humanized IgG1 (2H7) | Increased binding to FcγRIIIa and decreased CDC | Genentech/Roche/Biogen | Phase 3 trials in NHL and autoimmune diseases |
| Veltuzumab95-97 | I | Humanized IgG1 | Slower off-rate | Immunomedics | Phase 1/2 in NHL and ITP (including subcutaneous delivery) |
| AME-133V98 | I | Humanized IgG1 with modified Fc | Increased binding to CD20 and FcγRIIIa and increased ADCC | Applied Molecular Evolution/Eli Lilly | Phase 1/2 in NHL |
| PRO13192199 | I | Humanized IgG1 (ocrelizumab) with modified Fc | Increased FcγRIIIa binding and ADCC | Genentech | Phase 1/2 in NHL and CLL |
| GA101100-108 | II | Humanized IgG1 with afucosylated Fc | Enhanced FcγRIIIa binding, ADCC, and direct PCD | Glycart/Roche | Phase 2 in NHL and CLL phase 3 in CLL |
Adapted from Beers et al15 with permission.
ITP indicates idiopathic thrombocytopenic purpura.